SecBot SecBot

FENC

FENNEC PHARMACEUTICALS INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. A1· CIK 0001211583 Biotech & Drug Discovery
$10.15 +0.07 (+0.69%)
Oct 26 4:00 PM ET · prev $10.08
Market cap
$361.6M
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$18.00
+77% · range $16.00–20.00
Next earnings
Nov 5
in 9 days · EPS est. $0.11
1 year
+15.1%
from $8.82 · Oct 27
30 days
−7.3%
from $10.95
52-week range
$5.77–12.78
−21% from high · low Mar 30
Avg volume 20D
119.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$1.6M
0 buyers · 4 sellers · since May 11
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Orin Hirschman and affiliated entities (AIGH Capital Management, AIGH Investment Partners) filed an amended…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $1.6M.

  • InstitutionsBULLISH

    Q2 2026: 16 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.112 → $0.106 over 90 days. 1 up, 2 down in 30 days.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD1,727,069$18.6M
Nuveen, LLCDOUBLED131,482$1.4M
Trexquant Investment LPDOUBLED119,122$1.3M
CITADEL ADVISORS LLCTRIM71,032$763.6K
Qube Research & Technologies LtdADD58,292$626.6K
BNP PARIBAS FINANCIAL MARKETSDOUBLED36,727$394.8K
GOLDMAN SACHS GROUP INCTRIM33,452$359.6K
Squarepoint Ops LLCTRIM31,132$334.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy8Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +77%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 12, 2026B. Riley Securities
REITERATE
REITERATEBuy
Aug 12, 2026Wedbush
MAINTAIN
MAINTAINOutperform
May 22, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.6M
sold · 4 insiders
DateInsiderTypeValue
Oct 12, 2026
Evans Terry L
Chief Commercial Officer
AWARD$12.9K
Oct 12, 2026
Andrade Robert
CHIEF FINANCIAL OFFICER
AWARD$21.3K
Oct 12, 2026
Hackman Jeffrey S.
Chief Executive Officer
AWARD$12.3K
Oct 12, 2026
Sayad Pierre Sargis
Chief Medical Officer
AWARD$21.3K
Oct 12, 2026
Cioffi Christiana Marie
Chief Strategy Officer
AWARD$21.8K
Sep 30, 2026
Cioffi Christiana Marie
Chief Strategy Officer
AWARD156 sh
Sep 30, 2026
Evans Terry L
Chief Commercial Officer
AWARD168 sh
Sep 30, 2026
Sayad Pierre Sargis
Chief Medical Officer
AWARD168 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
$0.11
EPS estimate, this quarter
−5%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.11$0.06–$0.16-5.4%$18.9M
Next Q$0.14$0.09–$0.22-6.8%$20.7M
Current FY$0.32$0.20–$0.52+8.8%$72.6M
Next FY$0.95$0.63–$1.42+6.5%$103.1M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Orin Hirschman and affiliated entities (AIGH Capital Management, AIGH Investment Partners) filed an amended Schedule…
SC 13G/A — Impact 5/10
Oct 12, 2026 Insider
Evans Terry L was granted 2,326 shares
Chief Commercial Officer @ $5.53 ($12.9K)
Oct 12, 2026 Insider
Andrade Robert was granted 3,846 shares
CHIEF FINANCIAL OFFICER @ $5.53 ($21.3K)
Oct 12, 2026 Insider
Hackman Jeffrey S. was granted 2,224 shares
Chief Executive Officer @ $5.53 ($12.3K)
Sep 17, 2026 Other
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ
Aug 31, 2026 SEC
Two C-suite insiders at Fennec Pharmaceuticals (CFO and CMO) sold a combined $1.03M in open-market shares over a 5-day…
CLUSTER — Impact 4/10
Aug 31, 2026 SEC
Two Fennec Pharmaceuticals executives (CFO and CMO) sold a combined $1.03M in open-market shares over a 5-day window…
CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
1,727,069 shares ($18.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
FENC Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 17, 2026
Press release
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the…
Aug 11, 2026
Earnings
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~
Aug 11, 2026
Earnings date
FENC Q2 2026 Earnings Scheduled — 2026-08-11
Aug 6, 2026
Earnings date
FENC Q2 2026 Earnings Scheduled — 2026-08-06
Aug 5, 2026
Earnings
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty…

SecBot reports

13 filings · 5 press releases · 4 bullish · 0 bearish · 9 neutral
All FENC filing & press-release reports (18)